T-817MA is the new drug developed for treating Alzheimer’s disease by scientists at Boston University Alzheimer’s Disease Center and Boston Medical Center. The drug is reported to alter the course of the disease in patients already suffering from Alzheimer’s dementia. If T-817MA works well in the trials, it would be the first drug approved for Alzheimer’s disease after 2003 by the U.S. Food and Drug Administration (FDA).
In direct response to recommendations made by a National Institutes of Health (NIH) scientific consensus panel, the ECOG-ACRIN Cancer Research Group announced today the opening of E4112, a clinical trial for women with newly diagnosed ductal carcinoma in situ (DCIS) of the breast who, together with their doctors, will use the results of a magnetic resonance imaging (MRI) exam to determine whether to undergo a lumpectomy or a mastectomy. Following that decision, patients and their doctors will use the results of the Oncotype DX® genomic test for DCIS to decide whether to undergo radiation following lumpectomy.
Do you have any queries?